A randomized controlled trial evaluating sildenafil citrate in relieving ureteral stent-related symptoms
Tóm tắt
To evaluate the role of sildenafil in relieving ureteral stent symptoms. A randomized controlled trial was conducted between March 2014 and November 2016. It included adult men who underwent unilateral ureteric stent after ureteroscopy. Patients who were taking PDE5-Is, alpha-blockers or anticholinergics, had contraindication to sildenafil or developed postoperative complications were not included. Eligible patients were randomized using sealed closed envelops to one of two groups (S and C). Patients in group S received sildenafil citrate 50 mg tablet once daily. Patients in group C were the control. All patients answered the ureteral stent symptom questionnaire (USSQ) after 2 weeks of stenting. Primary outcome was the difference in total USSQ score between both groups. Secondary outcomes were tolerability of the treatment and the difference in each domain of USSQ score. After randomization, four patients (7.3%) in group C withdraw their consent because of severe symptoms and two patients (3.6%) in group S discontinued treatment because of headache and dizziness. Final analysis was performed for 46 and 48 patients in groups C and S, respectively. Total USSQ score and all domains (except work performance) were significantly lower in group S (P < 0.001). Dysuria and urgency were significantly more in group C (P = 0.012 and 0.007, respectively). Three patients in groups S (6.25%) experienced transient mild adverse effects (dyspepsia, flushing and rhinitis in one patient for each) but they continued sildenafil. Sildenafil is an effective and well-tolerated treatment option for relieving ureteral stent-related symptoms in men. NCT02345980.
Tài liệu tham khảo
Scameciu I, Lupu S, Pricop C, Morbidity SC (2015) Impact on quality of life in patients with indwelling ureteral stents: a 10-year clinical experience. Pak J Med Sci 31:522–526
El-nahas A, El-assmy A, Shoma A, Eraky I, El-kenawy M, El-kappany H (2006) Self-retaining ureteral stents: analysis of factors responsible for patients’ discomfort. J Endourol 20:33–37
Lingeman JE, Preminger GM, Goldfischer ER, Krambeck AE (2009) Assessing the impact of ureteral stent design on patient comfort. J Urol 181:2581–2587
Dellis A, Joshi HB, Timoney AG, Keeley FX Jr (2010) Relief of stent related symptoms: review of engineering and pharmacological solutions. J Urol 184:1267–1272
Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ (2011) Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int 108:1894–1902
Zhou L, Cai X, Li H, Wang KJ (2015) Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 29:650–656
Koprowski C, Kim C, Modi PK, Elsamra SE (2016) Ureteral stent-associated pain: a review. J Endourol 30:744–753
Gacci M, Corona G, Salvi M et al (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003
Zhang LT, Park JK (2015) Are phosphodiesterase type 5 inhibitors effective for the management of lower urinary symptoms suggestive of benign prostatic hyperplasia? World J Nephrol 4:138–147
Oger S, Behr-Roussel D, Gorny D et al (2010) Signalling pathways involved in sildenafil-induced relaxation of human bladder dome smooth muscle. Br J Pharmacol 160:1135–1143
Gacci M, del Popolo G, Macchiarella A, Celso M et al (2007) Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 178:2040–2043
Shokeir AA, Tharwat MA, Abolazm AE, Harraz A (2016) Sildenafil citrate as a medical expulsive therapy for distal ureteric stones: a randomised double-blind placebo-controlled study. Arab J Urol. 14:1–6
Aggarwal SP, Priyadarshi S, Tomar V (2015) A randomized controlled trial to compare the safety and efficacy of tadalafil and tamsulosin in relieving double J stent related symptoms. Adv Urol 2015:592175
El-Nahas AR, El-saadony MM, Tharwat M et al (2014) Validation of Arabic linguistic version of ureteral stent symptoms questionnaire. Arab J Urol 12:290–293
Mendez-Probst CE, Goneau LW, MacDonald KW et al (2012) The use of triclosan eluting stents effectively reduces ureteral stent symptoms: a prospective randomized trial.”. BJU Int 110:749–754
Krambeck AE, Walsh RS, Denstedt JD et al (2010) A novel drug eluting ureteral stent: a prospective, randomized, multicenter clinical trial to evaluate the safety and effectiveness of a ketorolac loaded ureteral stent. J Urol 183:1037–1042
McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G (2007) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071–1077
Fibbi B, Morelli A, Vignozzi L et al (2010) Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7:59–69
Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506–516
Gratzke C, Ückert S, Kedia G et al (2007) In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 35:49–54